{"id":204879,"date":"2025-10-06T11:17:08","date_gmt":"2025-10-06T11:17:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/204879\/"},"modified":"2025-10-06T11:17:08","modified_gmt":"2025-10-06T11:17:08","slug":"lyra-therapeutics-announces-clinical-plan-for-lyr-210-and-late-breaking-oral-presentation-of-phase-3-enlighten-2-study","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/204879\/","title":{"rendered":"Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study"},"content":{"rendered":"<p>&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n<p>Lyra Therapeutics (Nasdaq: LYRA) outlined a clinical plan for LYR-210 after a September 2025 FDA meeting and announced a late-breaking oral presentation of positive Phase 3 ENLIGHTEN 2 results at AAO-HNS on October 13, 2025.<\/p>\n<p>ENLIGHTEN 2 met its primary endpoint with statistically significant improvement in the three-cardinal-symptom composite at week 24 in patients without nasal polyps, met key secondary endpoints in the full population and SNOT-22 at week 24, and showed symptom improvement as early as week 4. LYR-210 was generally well tolerated with a safety profile similar to sham. The implant is designed to deliver six months of continuous local anti-inflammatory therapy.<\/p>\n<p>The FDA confirmed that Lyra must conduct an additional clinical trial before an NDA submission for CRS without nasal polyps; Lyra plans to refine that trial using ENLIGHTEN learnings.<\/p>\n<p>Lyra Therapeutics (Nasdaq: LYRA) ha delineato un piano clinico per LYR-210 dopo l&#8217;incontro della FDA di settembre 2025 e ha annunciato una presentazione orale dell&#8217;esito positivo di Fase 3 ENLIGHTEN 2 all&#8217;AAO-HNS il 13 ottobre 2025.<\/p>\n<p>ENLIGHTEN 2 ha raggiunto l&#8217;endpoint primario con un miglioramento statisticamente significativo nel composito dei tre sintomi cardinali alla settimana 24 in pazienti senza polipi nasali, ha raggiunto i principali endpoint secondari nella popolazione totale e nel SNOT-22 alla settimana 24, e ha mostrato un miglioramento dei sintomi gi\u00e0 dalla settimana 4. LYR-210 \u00e8 stato generalmente ben tollerato con un profilo di sicurezza simile al trattamento simulato. L&#8217;impianto \u00e8 progettato per fornire sei mesi di terapia antinfiammatoria locale continua.<\/p>\n<p>La FDA ha confermato che Lyra deve condurre uno studio clinico aggiuntivo prima della presentazione di NDA per CRS senza polipi nasali; Lyra intende perfezionare tale studio utilizzando gli apprendimenti di ENLIGHTEN.<\/p>\n<p>Lyra Therapeutics (Nasdaq: LYRA) deline\u00f3 un plan cl\u00ednico para LYR-210 tras la reuni\u00f3n de la FDA de septiembre de 2025 y anunci\u00f3 una presentaci\u00f3n oral de resultados positivos de Fase 3 ENLIGHTEN 2 en la AAO-HNS el 13 de octubre de 2025.<\/p>\n<p>ENLIGHTEN 2 cumpli\u00f3 su endpoint primario con una mejora estad\u00edsticamente significativa en el compuesto de los tres s\u00edntomas cardinales en la semana 24 en pacientes sin p\u00f3lipos nasales, alcanz\u00f3 los endpoints secundarios clave en la poblaci\u00f3n total y en el SNOT-22 en la semana 24, y mostr\u00f3 mejora de los s\u00edntomas tan pronto como la semana 4. LYR-210 fue generalmente bien tolerado con un perfil de seguridad similar al de la simulaci\u00f3n. El implante est\u00e1 dise\u00f1ado para proporcionar seis meses de terapia antiinflamatoria local continua.<\/p>\n<p>La FDA confirm\u00f3 que Lyra debe realizar un ensayo cl\u00ednico adicional antes de la presentaci\u00f3n de NDA para CRS sin p\u00f3lipos nasales; Lyra planea refinar ese ensayo utilizando los aprendizajes de ENLIGHTEN.<\/p>\n<p>Lyra Therapeutics (\ub098\uc2a4\ub2e5: LYRA)\ub294 LYR-210\uc5d0 \ub300\ud55c \uc784\uc0c1 \uacc4\ud68d\uc744 2025\ub144 9\uc6d4 FDA \ubbf8\ud305 \ud6c4 \uc81c\uc2dc\ud558\uace0 2025\ub144 10\uc6d4 13\uc77c AAO-HNS\uc5d0\uc11c ENLIGHTEN 2\uc758 \uc591\uc131 3\uc0c1 \uacb0\uacfc\ub97c  \ubc1c\ud45c\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>ENLIGHTEN 2\ub294 \ube44\ube44\uac15 \ud3f4\ub9bd \ud658\uc790\uc5d0\uc11c 24\uc8fc \ucc28\uc758 3\uac00\uc9c0 \uc8fc\uc694 \uc99d\uc0c1 \ubcf5\ud569 \uc9c0\ud45c\uc5d0\uc11c \ud1b5\uacc4\uc801\uc73c\ub85c \uc720\uc758\ud55c \uac1c\uc120\uc744 \uc785\uc99d\ud588\uace0, \uc804\uccb4 \uc778\uad6c \ubc0f SNOT-22\uc5d0\uc11c 24\uc8fc \ucc28\uc5d0 \uc8fc\uc694 2\ucc28 \uc9c0\ud45c\ub97c \ub2ec\uc131\ud588\uc73c\uba70, \uc99d\uc0c1\uc740 4\uc8fc \ucc28\ubd80\ud130 \uac1c\uc120\ub418\uae30 \uc2dc\uc791\ud588\uc2b5\ub2c8\ub2e4. LYR-210\uc740 \uc704\uc57d\uacfc \uc720\uc0ac\ud55c \uc548\uc804\uc131 \ud504\ub85c\ud30c\uc77c\uc744 \ubcf4\uc774\uba70 \uc77c\ubc18\uc801\uc73c\ub85c \ub0b4\uc57d\uc131\uc774 \uc591\ud638\ud588\uc2b5\ub2c8\ub2e4. \uc774 \uc784\ud50c\ub780\ud2b8\ub294 6\uac1c\uc6d4\uac04\uc758 \uc5f0\uc18d\uc801\uc778 \uad6d\uc18c \ud56d\uc5fc \uce58\ub8cc\ub97c \uc81c\uacf5\ud558\ub3c4\ub85d \uc124\uacc4\ub418\uc5c8\uc2b5\ub2c8\ub2e4.<\/p>\n<p>FDA\ub294 CRS \ubb34\ud3f4\ub9bd \ube44\uac15 \ud3f4\ub9bd\uc5d0 \ub300\ud55c NDA \uc81c\ucd9c \uc804\uc5d0 \ucd94\uac00 \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc218\ud589\ud574\uc57c \ud55c\ub2e4\uace0 \ud655\uc778\ud588\uc73c\uba70, Lyra\ub294 ENLIGHTEN\uc758 \ud559\uc2b5\uc744 \ud65c\uc6a9\ud574 \ud574\ub2f9 \uc2dc\ud5d8\uc744 \ub2e4\ub4ec\uc744 \uacc4\ud68d\uc785\ub2c8\ub2e4.<\/p>\n<p>Lyra Therapeutics (Nasdaq : LYRA) a d\u00e9crit un plan clinique pour LYR-210 apr\u00e8s une r\u00e9union de la FDA en septembre 2025 et a annonc\u00e9 une pr\u00e9sentation orale de derni\u00e8re minute des r\u00e9sultats positifs de la phase 3 ENLIGHTEN 2 \u00e0 l&#8217;AAO-HNS le 13 octobre 2025.<\/p>\n<p>ENLIGHTEN 2 a atteint son endpoint primaire avec une am\u00e9lioration statistiquement significative du composite des trois sympt\u00f4mes cardinaux \u00e0 la semaine 24 chez les patients sans polypes nasaux, a atteint les endpoints secondaires cl\u00e9s dans la population enti\u00e8re et le SNOT-22 \u00e0 la semaine 24, et a montr\u00e9 une am\u00e9lioration des sympt\u00f4mes d\u00e8s la semaine 4. LYR-210 a \u00e9t\u00e9 g\u00e9n\u00e9ralement bien tol\u00e9r\u00e9 avec un profil de s\u00e9curit\u00e9 similaire au sham. L\u2019implant est con\u00e7u pour d\u00e9livrer six mois de th\u00e9rapie anti-inflammatoire locale continue.<\/p>\n<p>La FDA a confirm\u00e9 que Lyra doit mener un essai clinique suppl\u00e9mentaire avant une soumission NDA pour les CRS sans polypes nasaux ; Lyra pr\u00e9voit d\u2019affiner cet essai en utilisant les enseignements d\u2019ENLIGHTEN.<\/p>\n<p>Lyra Therapeutics (Nasdaq: LYRA) skizzierte einen klinischen Plan f\u00fcr LYR-210 nach einem FDA-Treffen im September 2025 und k\u00fcndigte eine sp\u00e4te m\u00fcndliche Pr\u00e4sentation der positiven Phase-3-Ergebnisse ENLIGHTEN 2 beim AAO-HNS am 13. Oktober 2025 an.<\/p>\n<p>ENLIGHTEN 2 erreichte den prim\u00e4ren Endpunkt mit einer statistisch signifikanten Verbesserung im Drei-Symptomen-Kernkompositum der Woche 24 bei Patienten ohne Nasenpolypen, erreichte wichtige sekund\u00e4re Endpunkte in der Gesamtpopulation und beim SNOT-22-Wert der Woche 24 und zeigte eine Symptomverbesserung bereits ab Woche 4. LYR-210 war insgesamt gut vertr\u00e4glich mit einem Sicherheitsprofil, das dem der Scheinbehandlung \u00e4hnelte. Die Implantation ist darauf ausgelegt, sechs Monate kontinuierliche lokale Antiinflammations-Therapie zu liefern.<\/p>\n<p>Die FDA best\u00e4tigte, dass Lyra vor einer NDA-Einreichung f\u00fcr CRS ohne Nasenpolypen eine zus\u00e4tzliche klinische Studie durchf\u00fchren muss; Lyra plant, diese Studie basierend auf den Erkenntnissen aus ENLIGHTEN zu verfeinern.<\/p>\n<p>Lyra Therapeutics (\u0646\u0627\u0633\u062f\u0627\u0643: LYRA) \u062d\u062f\u062f\u062a \u062e\u0637\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0640 LYR-210 \u0628\u0639\u062f \u0627\u062c\u062a\u0645\u0627\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0641\u064a \u0633\u0628\u062a\u0645\u0628\u0631 2025 \u0648\u0623\u0639\u0644\u0646\u062a \u0639\u0646 \u0639\u0631\u0636 \u0634\u0641\u0647\u064a \u0641\u064a \u0622\u062e\u0631 \u0644\u062d\u0638\u0629 \u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 ENLIGHTEN 2 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 AAO-HNS \u064a\u0648\u0645 13 \u0623\u0643\u062a\u0648\u0628\u0631 2025.<\/p>\n<p>\u062d\u0642\u0642\u062a ENLIGHTEN 2 \u0647\u062f\u0641\u0647\u0627 \u0627\u0644\u0623\u0648\u0644\u064a \u0628\u062a\u062d\u0633\u0646 \u0630\u064a \u062f\u0644\u0627\u0644\u0629 \u0625\u062d\u0635\u0627\u0626\u064a\u0629 \u0641\u064a \u0645\u0643\u0648\u0651\u0628 \u0627\u0644\u0623\u0639\u0645\u062f\u0629 \u0627\u0644\u062b\u0644\u0627\u062b\u0629 \u0644\u0644\u0623\u0639\u0631\u0627\u0636 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0623\u0633\u0628\u0648\u0639 24 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0628\u062f\u0648\u0646 \u0632\u0648\u0627\u0626\u062f \u0623\u0646\u0641\u064a\u0629\u060c \u0648\u062d\u0642\u0642\u062a \u0623\u0647\u062f\u0627\u0641 \u062b\u0627\u0646\u0648\u064a\u0629 \u0631\u0626\u064a\u0633\u064a\u0629 \u0641\u064a \u062c\u0645\u064a\u0639 \u0627\u0644\u0633\u0643\u0627\u0646 \u0648SNOT-22 \u0641\u064a \u0627\u0644\u0623\u0633\u0628\u0648\u0639 24\u060c \u0648\u0623\u0638\u0647\u0631\u062a \u062a\u062d\u0633\u0646\u064b\u0627 \u0641\u064a \u0627\u0644\u0623\u0639\u0631\u0627\u0636 \u0628\u062f\u0621\u064b\u0627 \u0645\u0646 \u0627\u0644\u0623\u0633\u0628\u0648\u0639 4. \u0643\u0627\u0646 LYR-210 \u0628\u0634\u0643\u0644 \u0639\u0627\u0645 \u0645\u062a\u0642\u0628\u0644\u064b\u0627 \u062c\u064a\u062f\u064b\u0627 \u0645\u0639 \u0645\u0644\u0641 \u0623\u0645\u0627\u0646 \u0645\u0634\u0627\u0628\u0647 \u0644\u0640 sham. \u062a\u0645 \u062a\u0635\u0645\u064a\u0645 \u0627\u0644\u0632\u0631\u0639\u0629 \u0644\u062a\u0648\u0641\u064a\u0631 \u0633\u062a\u0629 \u0623\u0634\u0647\u0631 \u0645\u0646 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u062d\u0644\u064a \u0627\u0644\u0645\u0636\u0627\u062f \u0644\u0644\u0627\u0644\u062a\u0647\u0627\u0628\u0627\u062a \u0628\u0634\u0643\u0644 \u0645\u0633\u062a\u0645\u0631.<\/p>\n<p> \u0623\u0643\u062f\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0623\u0646 Lyra \u064a\u062c\u0628 \u0625\u062c\u0631\u0627\u0621 \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0625\u0636\u0627\u0641\u064a\u0629 \u0642\u0628\u0644 \u0627\u0644\u062a\u0642\u062f\u0645 \u0628\u0637\u0644\u0628 NDA \u0644\u0640 CRS \u0628\u062f\u0648\u0646 \u0632\u0648\u0627\u0626\u062f \u0623\u0646\u0641\u064a\u0629\u061b \u062a\u062e\u0637\u0637 Lyra \u0644\u0635\u0642\u0644 \u062a\u0644\u0643 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u062f\u0631\u0648\u0633 \u0627\u0644\u0645\u0633\u062a\u0641\u0627\u062f\u0629 \u0645\u0646 ENLIGHTEN.<\/p>\n<p>Lyra Therapeutics (\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aLYRA) \u57282025\u5e749\u6708\u7684FDA\u4f1a\u8bae\u4e4b\u540e\u6982\u8ff0\u4e86&lt;0&gt;LYR-2100&gt;\u7684\u4e34\u5e8a\u8ba1\u5212\uff0c\u5e76\u5ba3\u5e03\u5728&lt;0&gt;2025\u5e7410\u670813\u65e50&gt;\u4e8eAAO-HNS\u4e3e\u884c\u7684ENLIGHTEN 2 III \u671f\u7ed3\u679c\u7684\u665a\u671f\u53e3\u5934\u62a5\u544a\u3002<\/p>\n<p>ENLIGHTEN 2\u5728\u7b2c24\u5468\u5bf9\u65e0\u9f3b\u8154\u606f\u8089\u60a3\u8005\u7684\u4e09\u5927\u75c7\u72b6\u7efc\u5408\u6307\u6807\u663e\u793a&lt;0&gt;\u7edf\u8ba1\u5b66\u663e\u8457\u76840&gt;\u6539\u5584\uff0c\u5728\u603b\u4f53\u4eba\u7fa4\u548cSNOT-22\u7684\u7b2c24\u5468\u8fbe\u5230\u4e86\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\uff0c\u5e76\u4e14\u75c7\u72b6\u6539\u5584\u4ece\u7b2c4\u5468\u5c31\u5df2\u5f00\u59cb\u3002LYR-210\u603b\u4f53\u8010\u53d7\u6027\u826f\u597d\uff0c\u5b89\u5168\u6027\u7279\u5f81\u4e0e\u5047\u624b\u672f\u7ec4\u76f8\u4f3c\u3002\u8be5\u690d\u5165\u7269\u8bbe\u8ba1\u7528\u4e8e\u63d0\u4f9b\u516d\u4e2a\u6708\u7684\u6301\u7eed\u5c40\u90e8\u6297\u708e\u6cbb\u7597\u3002<\/p>\n<p>FDA\u786e\u8ba4Lyra\u5728\u5c31 CRS \u65e0\u9f3b\u8154\u606f\u8089\u7684 NDA \u63d0\u4ea4\u4e4b\u524d\u9700\u8981\u8fdb\u884c\u53e6\u4e00\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\uff1bLyra\u8ba1\u5212\u5229\u7528 ENLIGHTEN \u7684\u7ecf\u9a8c\u6559\u8bad\u6765\u5b8c\u5584\u8be5\u8bd5\u9a8c\u3002<\/p>\n<p>Positive<\/p>\n<p>          &#13;<br \/>\n            &#13;<br \/>\n                    Primary endpoint met at week 24 in patients without nasal polyps&#13;<br \/>\n            &#13;<br \/>\n                    Key secondary endpoints met including full population 3CS and SNOT-22 at week 24&#13;<br \/>\n            &#13;<br \/>\n                    Symptom improvement observed as early as week 4&#13;<br \/>\n            &#13;<br \/>\n                    Safety profile generally well tolerated and similar to sham control&#13;<br \/>\n            &#13;<br \/>\n                    Implant designed for six-month continuous local drug delivery&#13;<br \/>\n            &#13;<\/p>\n<p>Negative<\/p>\n<p>          &#13;<br \/>\n            &#13;<br \/>\n                    FDA requires an additional clinical trial before NDA submission for CRS without nasal polyps&#13;<br \/>\n            &#13;<br \/>\n                    Additional trial likely delays NDA timing and market access pathway&#13;<br \/>\n            &#13;<\/p>\n<p>      &#13;<\/p>\n<p>&#13;<br \/>\n          Insights  &#13;\n        <\/p>\n<p>&#13;<br \/>\n    &#13;<\/p>\n<p class=\"tldr\">Positive Phase 3 results confirmed, but FDA requires one more trial before NDA; program advances with a defined next step.<\/p>\n<p>LYR-210 met its primary endpoint at week 24 in patients without nasal polyps and achieved key secondary endpoints, including 3CS in the full population and SNOT-22 at week 24, with symptom improvement as early as week 4<\/p>\n<p>The FDA meeting in September 2025 clarified that an additional clinical trial in patients without nasal polyps is required for an NDA; this sets a clear regulatory path but adds time and execution risk tied to trial design, enrollment, and results.<\/p>\n<p>Watch for the finalized protocol and timelines for the new trial, presentation details at AAO-HNS on October 13, and any operational guidance on endpoints or statistical plans; expect a multi-quarter horizon to completion and readout depending on design and enrollment pace.<\/p>\n<p>          &#13;<br \/>\n        &#13;<\/p>\n<p>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      10\/06\/2025 &#8211; 07:00 AM&#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n<p>Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission\u00a0<\/p>\n<p>Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting<\/p>\n<p>WATERTOWN, Mass., Oct.  06, 2025  (GLOBE NEWSWIRE) &#8212; <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=s4AzjGDah6MP4pWRSY2LaCJjVtuaaBxAV3bbmz7FlycsgbvllMp5vy4mPqCKwelMg7nkXTVQFaDe0sspopiPGEJQ213QqSHcqOwas52SjjE=\" target=\"_blank\">Lyra Therapeutics, Inc.<\/a>\u00a0(Nasdaq: <a href=\"https:\/\/www.stocktitan.net\/overview\/LYRA\" title=\"View LYRA stock overview\" class=\"symbol-link\" rel=\"nofollow noopener\" target=\"_blank\">LYRA<\/a>), (\u201cLyra\u201d or the \u201cCompany\u201d), a late clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS),\u00a0today announced the Company\u2019s clinical plan and upcoming oral presentation of results from the positive Phase 3 ENLIGHTEN 2 trial for LYR-210, the company\u2019s lead product candidate for CRS.<\/p>\n<p>Lyra plans to proceed with an additional clinical trial that was confirmed as a requirement for submission of a New Drug Application (\u201cNDA\u201d)\u00a0for LYR-210 for the treatment of CRS without nasal polyps, based on a September 2025 meeting with the U.S. Food and Drug Administration\u00a0(\u201cFDA\u201d).<\/p>\n<p>&#8220;Now that we have clarity on the path forward for LYR-210, we are focused on advancing a third clinical trial in patients without nasal polyps. We plan to refine the design of this new trial based on the learnings of ENLIGHTEN 1 and ENLIGHTEN 2 and FDA feedback,\u201d said Maria Palasis, Ph.D., President and CEO, Lyra Therapeutics. &#8220;We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management.\u201d<\/p>\n<p>Lyra also announced a late-breaking oral presentation of the positive ENLIGHTEN 2 Phase 3 results at the Annual Meeting of the American Academy of Otolaryngology\u2013Head and Neck Surgery (AAO-HNS), taking place October 11-14 in Indianapolis.<\/p>\n<p>Late-Breaking Scientific Oral Presentation<\/p>\n<p>  Title:\u00a0LYR-210 Long-Acting Sinonasal Implants for Chronic Rhinosinusitis: Results from the Phase 3 ENLIGHTEN 2 StudyPresenting Author:\u00a0Zachary M. Soler, M.D., M.Sc., Medical University of South CarolinaCo-Authors: Jivianne T. Lee, M.D., Professor, UCLA School of Medicine; Robert M. Naclerio, M.D., Johns Hopkins University; Brent A. Senior, M.D., Harold C. Pillsbury, III Distinguished Professor, Department of Otolaryngology Head &amp; Neck Surgery, University of North Caroline School of Medicine; Robert Kern, M.D., Northwestern Medical; Vineeta S. Belanger, Ph.D., SVP, Clinical Affairs, Lyra TherapeuticsDate and Time:\u00a0Monday, October 13\u00a0at 4:48 p.m. ET  <\/p>\n<p>In June 2025, Lyra announced <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=t1lGtCWIblvyHtnY9dEwv9q6gdFT3KiQVpXXgsHyUYrbFDnx0cxn7eBrekYM1vYElH-R1bhkD1kWBMG0Hx4FHN9NSJKhqSMhBFkJ8EU0v-pn5LdPxxcte33_sRxl98Nv1SNOFCCHoSE5n-3T1sRHXKQWHSfJijizgQ_GKlGtAA44xGrNvbgFQMrtW9ezvSgtGR4BGEEXv9P7EPG3tRxMfRSSlmX2EeRTUcxE-Tyul2HgmC3foFJUjxbm-42dqr8qbrYRvxo3Hd6Qsa2nxBcUHCTzlkiBJuhXPAnA3m8R_gw=\" target=\"_blank\">positive results from the ENLIGHTEN 2 Phase 3 clinical trial<\/a> of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain\/pressure) at week 24 in patients without nasal polyps. The ENLIGHTEN 2 trial also met the key secondary endpoints of 3CS at 24 weeks in the full population (i.e., patients with and without nasal polyps) and in the clinically-validated SNOT-22 score at 24 weeks, with symptom improvement observed as early as week 4. Consistent with previous studies, LYR-210 was generally well-tolerated, with a safety profile similar to sham control. The 24-week endpoints in the ENLIGHTEN trials assess LYR-210\u2019s long-acting therapeutic effect as a bioresorbable sinonasal implant designed to deliver six months of continuous anti-inflammatory medication to the sinonasal passages.<\/p>\n<p>About LYR-210<\/p>\n<p>LYR-210 is an investigational product candidate for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. LYR-210 is a bioabsorbable sinonasal implant designed to be inserted in a simple, in-office procedure. LYR-210 is intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat CRS. LYR-210 is being evaluated in the ENLIGHTEN pivotal Phase 3 clinical program.<\/p>\n<p>About Lyra Therapeutics<\/p>\n<p><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=s4AzjGDah6MP4pWRSY2LaCJjVtuaaBxAV3bbmz7Flydv06dz9fEqXYX6378rVkzwmDLZkoohEeRULN2F4t6DyZd-6vHljKEv3SKzj4yX8_o=\" target=\"_blank\">Lyra Therapeutics, Inc.<\/a> is a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS). Lyra Therapeutics is developing therapies for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210, the company\u2019s lead product candidate, is a bioabsorbable sinonasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy (7500\u00b5g mometasone furoate) to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase 3 clinical program, is intended for patients with and without nasal polyps. The Company\u2019s therapies are intended to treat the estimated four million CRS patients in the United States who fail medical management each year. For more information, please visit <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=NhpQENTwFM6O2yuo22OaAn6ObyPAZoMW23iggQw6AE0KTmHyfRuohT3NAtjOGqyOCG0mCJZhhDbae_35j6syXA==\" target=\"_blank\">www.lyra.com<\/a>\u00a0and follow us on <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=KpM1JngpwjoZ4XhtbPUcyfw1fUNzjddsPzoYj2qTiRtsEV0mF7SW4HG55CHbYz_X9Re40Az1OCrEfGsF5vqBT-rWo8nGy8j0VR1bvrUnpfitPKK1TIoy9amADPOtWxm_\" target=\"_blank\">LinkedIn<\/a>. \u00a0<\/p>\n<p>Forward-Looking Statements<\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplan\u201d, \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d and similar expressions are intended to identify forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company\u2019s cash runway into the third quarter of 2026, whether LYR-210 could potentially benefit patients with CRS with or without polyps,\u00a0the safety, efficacy, potential benefits of, and clinical design or progress of LYR-210 at any dosage or in any indication; the in-house CMC activities to prepare for manufacturing LYR-210 for potential, future clinical trials and for compliance with applicable CMC regulations; our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates; the Company\u2019s business strategy and plans; and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the Company\u2019s failure to meet its primary endpoint in its ENLIGHTEN 1 Phase 3 clinical trial; the fact that the Company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future; the Company&#8217;s need for additional funding, which may not be available; the Company\u2019s ability to continue as a going concern; the Company\u2019s limited operating history; the fact that the Company has no approved products; the fact that clinical trial data is subject to change until the completion of the applicable clinical study report; the fact that clinical trials required for the Company\u2019s product candidates are expensive and time-consuming, and their outcome is uncertain; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the Company&#8217;s reliance on third parties to conduct its preclinical studies and clinical trials; failure to obtain and maintain or adequately protect the Company&#8217;s intellectual property rights; the Company\u2019s failure to regain compliance with, or continue to meet, the listing requirements of the Nasdaq Capital Market and be delisted; the Company\u2019s failure to retain key personnel; the fact that the price of the Company&#8217;s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption &#8220;Risk Factors&#8221; in the Company\u2019s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management&#8217;s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.<\/p>\n<p> <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/ti\"\/> <br \/><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/Lyra-Therapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>Contact Information:<br \/>\nJason Cavalier, Chief Financial Officer<br \/>\n917.584.7668<br \/>\njcavalier@lyratx.com<\/p>\n<p>Media Contact:<br \/>\nKathryn Morris, The Yates Network LLC<br \/>\n914.204.6412<br \/>\nkathryn@theyatesnetwork.com&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n  &#13;<br \/>\n&#13;<\/p>\n<p>&#13;<br \/>\n    FAQ  &#13;\n  <\/p>\n<p>&#13;<br \/>\n  &#13;<br \/>\n  &#13;<\/p>\n<p>        What did Lyra announce about LYR-210 after the September 2025 FDA meeting?<\/p>\n<p>&#13;<br \/>\n          The company said the FDA confirmed an additional clinical trial is required before an NDA submission for CRS without nasal polyps.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What were the key ENLIGHTEN 2 Phase 3 results for LYR-210 (LYRA)?<\/p>\n<p>&#13;<br \/>\n          ENLIGHTEN 2 met its primary endpoint at week 24 in patients without nasal polyps and met key secondary endpoints including SNOT-22 at week 24.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        When and where will Lyra present the ENLIGHTEN 2 results?<\/p>\n<p>&#13;<br \/>\n          A late-breaking oral presentation is scheduled for October 13, 2025 at 4:48 p.m. ET at the AAO-HNS Annual Meeting in Indianapolis.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        How long is LYR-210 designed to deliver therapy for CRS patients?<\/p>\n<p>&#13;<br \/>\n          LYR-210 is designed to provide six months of continuous anti-inflammatory medication via a bioresorbable sinonasal implant.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        Did ENLIGHTEN 2 report any safety concerns for LYR-210?<\/p>\n<p>&#13;<br \/>\n          The trial reported LYR-210 was generally well tolerated with a safety profile similar to sham control.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What is the investor impact of the FDA&#8217;s requirement for an additional trial for LYRA?<\/p>\n<p>&#13;<br \/>\n          The requirement means Lyra will conduct another clinical trial, which could delay NDA submission timing for CRS without nasal polyps.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; &#13; &#13; &#13; &#13; &#13; &#13; &#13; Lyra Therapeutics (Nasdaq: LYRA) outlined a clinical plan for LYR-210&hellip;\n","protected":false},"author":2,"featured_media":204880,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,117780,117778,117779,117777,3,452,453],"class_list":["post-204879","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-lyra-latest-news","tag-lyra-news","tag-lyra-stock","tag-lyra-stock-news","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/204879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=204879"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/204879\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/204880"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=204879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=204879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=204879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}